Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366325 | 0.82 | SMN1; SMN2 (0.45) | KDM4EKMT2AALDH1A1MEN1ADORA1 | |
| SCHEMBL11465109 | 0.80 | ADORA1 (0.46) | KDM4EKMT2AALDH1A1MEN1ADORA1 | |
| SCHEMBL11723044 | 0.78 | AR (0.44) | KDM4EKMT2AALDH1A1MEN1ADORA1 | |
| SCHEMBL11724059 | 0.78 | FABP4 (0.43) | KDM4EKMT2AALDH1A1MEN1ADORA1 | |
| SCHEMBL11726649 | 0.76 | KDM4E (0.39) | KDM4EKMT2AALDH1A1MEN1ADORA1 | |
| SCHEMBL11723632 | 0.76 | KDM4E (0.40) | KDM4EKMT2AALDH1A1MEN1ADORA1 | |
| SCHEMBL7978388 | 0.75 | ADORA1 (0.61) | KDM4EKMT2AALDH1A1MEN1ADORA1 | |
| SCHEMBL5368416 | 0.75 | LMNA (0.53) | KDM4EKMT2AALDH1A1MEN1ADORA1 | |
| SCHEMBL11591322 | 0.75 | KDM4E (0.53) | KDM4EKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL4136622 | 0.72 | PDE3B (0.47) | KDM4EKMT2AADORA1ADORA2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| EP-2155748-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008144268-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | WO | disclosed |
| EP-0446604-A2 | Pyridine and related aza heterocycle derivatives as cardiovascular agents | AMERICAN CYANAMID COMPANY (US) | 1991-09-18 | — | — | EP | disclosed |
| US-4229456-A | SUPPRESSION OF GASTRIC SECRETIONS | MERCK & CO., INC. (US) | 1980-10-21 | — | — | US | disclosed |
| EP-0000490-A1 | Substituted naphthyridinones, processes for their preparations and therapeutical applications | MERCK & CO. INC. (US) | 1979-02-07 | — | — | EP | disclosed |
| US-4133885-A | GASTRIC SECRETIONS INHIBITORS | MERCK & CO., INC. (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, AGTR1, AGTR2 | KDM4E 4548/4885KMT2A 3837/4885ALDH1A1 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.